P/B
6,7
Vertex Pharmaceuticals
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
$139.2B
Market Cap • 11/4/2026
1989
(37 years)
Founded
1991
(35 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
S&P500 Participant
Index Composite • 2026
Valuation
P/S
10,7
P/EBITDA
30,7
P/OCF
37,7
P/FCF
43,5
P/E
35,3
BVPS
82,5
EPS
15,5
Market Cap
Market Cap
139,2B
EV
139,4B
EV/Revenue
10,8
EV/EBITDA
30,7
EV/EBIT
32,4
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
0,9%
Total Yield
0,9%
Payout
0%
Retained Earnings
16,3B
Profitability
Gross Margin
85,5%
EBITDA Margin
35,1%
EBIT Margin
33,2%
Net Margin
30,7%
D&A/EBITDA
0%
R&D/Revenue
33,7%
Capex/Revenue
3,8%
Capex/D&A
207,5%
Capex/OCF
13,3%
SBC/OCF
18,1%
% PPE
10,2%
% Goodwill
7,4%
ROE
20,8%
ROIC
19,6%
Growth
CAGR Revenue 5Y
12,7%
CAGR Op. Income 5Y
10,2%
CAGR Net Income 5Y
12,8%
CAGR EPS 5Y
13,3%
CAGR OCF 5Y
11,5%
Leverage
N.D./EBITDA
0
Debt/Equity
0%
Current Ratio
2,3
Quick Ratio
1,7
Interest Coverage
9438,2%
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!